Proliferation, not replication: HIV is lifelong because infected cells divide, not only because they infect others
Gene therapy decreases HIV reservoir and moderately suppresses viral load in some
Thigh injections could be an option for long-acting cabotegravir and rilpivirine
Russia: Combining HIV and drug treatment doubles the proportion of opiate users who have an undetectable viral load
Top 5 stories on injectable HIV treatment and PrEP from CROI 2023
Top 5 stories on new drugs for HIV prevention and treatment from CROI 2023
Top 5 HIV treatment stories from CROI 2023
Top 5 stories on HIV in Africa from CROI 2023
Top 5 stories on sexual health from CROI 2023
Rapid adherence testing sheds light on viral suppression and resistance
Experimental islatravir implants protect monkeys against HIV-like virus
Tenofovir disoproxil-based pill regains its position as first choice for PrEP in the US
Huge increase in PrEP uptake when services offer choice and flexibility, African studies show
Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option
Failure of integrase inhibitor-based regimens may be due to a completely novel form of resistance
Weight loss after treatment switch more likely for those with higher body mass
White blood cell changes on islatravir do not lead to a higher risk of infections
HIV infections acquired while on injectable PrEP may take a very long time to be spotted
